Ed Dowd On Pfizer Increasing Their Revenue to $90B After Covid-19 | Ep. 244 | Part 1
PBD Podcast
00:00
Pfizer's Revenue Surge: Impact of COVID-19 on Pharmaceutical Profits
This chapter examines Pfizer's staggering revenue growth from $40 billion to $90 billion in the wake of the COVID-19 pandemic. It delves into the historical context of the company's financial success and the impact of pandemic-driven fears on public health policies and corporate profits.
Transcript
Play full episode
